Thieme E-Books & E-Journals -
Zurück
Aktuelle Urol 2025; 56(01): 71-76
DOI: 10.1055/a-2148-5799
Case Report

Enfortumab vedotin as a salvage option as 5th line therapy for metastatic urothelial bladder cancer

Enfortumab Vedotin als Salvage Option in Fünftlininentherapie beim metastasierten Blasenkarzinom
Melanie Klee
1   Department of Urology, Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lubeck, Germany (Ringgold ID: RIN54360)
,
Marie Christine Roesch
1   Department of Urology, Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lubeck, Germany (Ringgold ID: RIN54360)
,
Hendrik Eggers
2   Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Medizinische Hochschule Hannover, Hannover, Germany (Ringgold ID: RIN9177)
,
Philipp Ivanyi
3   Urology, MHH, Hannover, Germany (Ringgold ID: RIN9177)
,
Axel S. Merseburger
1   Department of Urology, Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lubeck, Germany (Ringgold ID: RIN54360)
,
Mario Kramer
1   Department of Urology, Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lubeck, Germany (Ringgold ID: RIN54360)
› Institutsangaben